266 related articles for article (PubMed ID: 31229187)
1. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.
Krawczyk N; Buresh M; Gordon MS; Blue TR; Fingerhood MI; Agus D
J Subst Abuse Treat; 2019 Aug; 103():1-8. PubMed ID: 31229187
[TBL] [Abstract][Full Text] [Related]
2. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
[TBL] [Abstract][Full Text] [Related]
3. Higher buprenorphine dose associated with increased treatment retention at low threshold buprenorphine clinic: A retrospective cohort study.
Selitsky L; Nordeck C; Truong A; Agus D; Buresh ME
J Subst Use Addict Treat; 2023 Apr; 147():208981. PubMed ID: 36804350
[TBL] [Abstract][Full Text] [Related]
4. Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City.
Truong C; Krawczyk N; Dejman M; Marshall-Shah S; Tormohlen K; Agus D; Bass J
Addict Behav; 2019 Jun; 93():14-19. PubMed ID: 30682677
[TBL] [Abstract][Full Text] [Related]
5. Low Threshold Telemedicine-based Opioid Treatment for Criminal Justice Involved Adults During the COVID-19 Pandemic: A Case Report.
Flavin L; Tofighi B; Krawczyk N; Schatz D; McNeely J; Butner J
J Addict Med; 2022 Jan-Feb 01; 16(1):e59-e61. PubMed ID: 35120069
[TBL] [Abstract][Full Text] [Related]
6. Routes of non-traditional entry into buprenorphine treatment programs.
Champagne-Langabeer T; Swank MW; Langabeer JR
Subst Abuse Treat Prev Policy; 2020 Jan; 15(1):6. PubMed ID: 31959194
[TBL] [Abstract][Full Text] [Related]
7. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail.
Lee JD; Malone M; McDonald R; Cheng A; Vasudevan K; Tofighi B; Garment A; Porter B; Goldfeld KS; Matteo M; Mangat J; Katyal M; Giftos J; MacDonald R
JAMA Netw Open; 2021 Sep; 4(9):e2123032. PubMed ID: 34495340
[TBL] [Abstract][Full Text] [Related]
9. "I want to stay here": Patient and staff perspectives on transitioning from a low-threshold buprenorphine program to clinic-based care.
Martinez NG; Truong AQ; Nordeck CD; Agus D; Genberg BL; Buresh ME
Drug Alcohol Depend; 2024 Apr; 257():111130. PubMed ID: 38452408
[TBL] [Abstract][Full Text] [Related]
10. Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine.
Krawczyk N; Picher CE; Feder KA; Saloner B
Health Aff (Millwood); 2017 Dec; 36(12):2046-2053. PubMed ID: 29200340
[TBL] [Abstract][Full Text] [Related]
11. Mobile low-threshold buprenorphine integrated with infectious disease services.
Rosecrans A; Harris R; Saxton RE; Cotterell M; Zoltick M; Willman C; Blackwell I; Bell J; Hayes D; Weir B; Sherman S; Lucas GM; Greenbaum A; Page KR
J Subst Abuse Treat; 2022 Feb; 133():108553. PubMed ID: 34238629
[TBL] [Abstract][Full Text] [Related]
12. Adapting a Low-threshold Buprenorphine Program for Vulnerable Populations During the COVID-19 Pandemic.
Nordeck CD; Buresh M; Krawczyk N; Fingerhood M; Agus D
J Addict Med; 2021 Sep-Oct 01; 15(5):364-369. PubMed ID: 33177436
[TBL] [Abstract][Full Text] [Related]
13. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
[TBL] [Abstract][Full Text] [Related]
14. Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation.
Belden C; Kopak A; Coules C; Friesen T; Hall J; Shukla S
J Subst Use Addict Treat; 2024 Jul; 162():209364. PubMed ID: 38626851
[TBL] [Abstract][Full Text] [Related]
15. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
[TBL] [Abstract][Full Text] [Related]
16. Low Barrier Tele-Buprenorphine in the Time of COVID-19: A Case Report.
Harris M; Johnson S; Mackin S; Saitz R; Walley AY; Taylor JL
J Addict Med; 2020; 14(4):e136-e138. PubMed ID: 32433364
[TBL] [Abstract][Full Text] [Related]
17. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco.
Carter J; Zevin B; Lum PJ
Addict Sci Clin Pract; 2019 May; 14(1):20. PubMed ID: 31060600
[TBL] [Abstract][Full Text] [Related]
18. Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation.
Jakubowski A; Rath C; Harocopos A; Wright M; Welch A; Kattan J; Navos Behrends C; Lopez-Castro T; Fox AD
Harm Reduct J; 2022 Jul; 19(1):75. PubMed ID: 35818071
[TBL] [Abstract][Full Text] [Related]
19. Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder.
Evans EA; Yoo C; Huang D; Saxon AJ; Hser YI
J Subst Abuse Treat; 2019 Nov; 106():19-28. PubMed ID: 31540607
[TBL] [Abstract][Full Text] [Related]
20. Criminal Justice Barriers to Treatment of Opioid Use Disorders in the United States: The Need for Public Health Advocacy.
Csete J
Am J Public Health; 2019 Mar; 109(3):419-422. PubMed ID: 30676805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
